Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Wilkinson

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Journal of Controlled Release : Official Journal of the Controlled Release Society|October 7, 2018
Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01Alexander Wilkinson, Eric Lattmann, Carla B Roces, et al.
The Lancet. Respiratory Medicine|March 3, 2019
Our patients and our planet-holistic considerations for inhaler choiceAlexander Wilkinson, Toby Hillman, Nicholas S Hopkinson, et al.
The European Respiratory Journal|July 1, 2022
The carbon footprint of respiratory treatments in Europe and Canada: an observational study from the CARBON programmeChrister Janson, Ekaterina Maslova, Alexander Wilkinson, et al.
The European Respiratory Journal|March 21, 2015
Noninterventional statistical comparison of BTS and CHEST guidelines for size and severity in primary pneumothoraxMarko Z Nikolić, Laurence S C Lok, Katharina Mattishent, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Journal of Controlled Release : Official Journal of the Controlled Release Society|October 7, 2018
Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01Alexander Wilkinson, Eric Lattmann, Carla B Roces, et al.
The Lancet. Respiratory Medicine|March 3, 2019
Our patients and our planet-holistic considerations for inhaler choiceAlexander Wilkinson, Toby Hillman, Nicholas S Hopkinson, et al.
The European Respiratory Journal|July 1, 2022
The carbon footprint of respiratory treatments in Europe and Canada: an observational study from the CARBON programmeChrister Janson, Ekaterina Maslova, Alexander Wilkinson, et al.
The European Respiratory Journal|March 21, 2015
Noninterventional statistical comparison of BTS and CHEST guidelines for size and severity in primary pneumothoraxMarko Z Nikolić, Laurence S C Lok, Katharina Mattishent, et al.
Pageof 2